Enovid is the brand name of the Nitric Oxide Nasal Spray (NONS) developed and manufactured by SaNOtize Research and Development Corp. based in Vancouver, BC, and marketed by IsraelPharm for our customers in the US. It is marketed under other brand names in other countries but not in the US or Canada. IsraelPharm is proud to supply Enovid to our customers.

Enovid is an anti-viral nasal spray device that creates a protective mechanical and chemical barrier against viruses within the nasal cavity. It contains easy-to-deliver doses of spray that lay down a barrier of nitric oxide designed to kill 99% of airborne viruses within 24 hours of treatment. Blocking entry of the COVID-19 virus via the upper respiratory tract has proven to be highly effective in preventing infection by the virus and reducing COVID-19 hospitalizations.

Many people infected by COVID-19 will feel symptoms similar to the flu. They can recover at home by getting enough rest, staying hydrated, and taking the usual influenza medications that reduce fever and relieve pain. The FDA has authorized three antiviral treatments for people with a more severe COVID-19 infection or higher risk factors for illness. Scientists continue working hard to develop other effective treatments. As with all other serious infectious diseases, prevention is better than cure. Using a practical and straightforward preventative treatment like Enovid will keep you much safer and less likely to need any other treatment.

It is possible to recognize that infection by the COVID-19 virus has set in, either from the symptoms alone or thanks to a positive test. In that case, contagion goes on for three to four days before and up to ten days after the first symptoms or the positive test. It is possible to go on infecting other people as long as seven days after the first signs.

In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19-infected subjects, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95% in viral replication. Within 72 hours, the SARS-CoV-2 viral load dropped by more than 99%. Most of these patients had been infected with the UK variant, considered a variant of concern.